CC-115 - Inxight Drugs

HHS Logo U.S. Department of Health & Human Services Divider Arrow NIH Logo National Institutes of Health Divider Arrow NIH Logo NCATS ncats logo ncats logo Return Home Inxight Drugs
  • Search Substances
  • Home
  • Browse Drugs
    • US Approved Drugs
    • Marketed Drugs
    • Investigational Drugs
    • All Substances
  • Search
    • Structure Search
    • Sequence Search
  • Downloads
  • About
  • Search Substances
CC-115 FII75TFH5L Investigational Source: NCT02977780: Phase 2 Interventional Recruiting Glioblastoma (2017) Source URL: https://clinicaltrials.gov/ct2/show/NCT02977780 CC-115 FII75TFH5L Investigational Source: NCT02977780: Phase 2 Interventional Recruiting Glioblastoma (2017) Source URL: https://clinicaltrials.gov/ct2/show/NCT02977780

Details

Stereochemistry ACHIRAL
Molecular Formula C16H16N8O
Molecular Weight 336.3512
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0
SHOW SMILES / InChI Structure of CC-115 SHOW STEREO... HIDE STEREO...
  • Structure Search

SMILES

CCN1C(=O)CNC2=C1N=C(C=N2)C3=C(C)N=C(C=C3)C4=NN=CN4

InChI

InChIKey=GMYLVKUGJMYTFB-UHFFFAOYSA-N InChI=1S/C16H16N8O/c1-3-24-13(25)7-18-15-16(24)22-12(6-17-15)10-4-5-11(21-9(10)2)14-19-8-20-23-14/h4-6,8H,3,7H2,1-2H3,(H,17,18)(H,19,20,23) HIDE SMILES / InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/27235137

CC-115 is a recently identified inhibitor of the mammalian Target of Rapamycin Kinase (TORK) and DNA-Dependent Protein Kinase (DNA-PK). It is under investigation in phase II clinical trials for the treatment for Glioblastoma and in phase I trials for the treatment of prostate cancer, Ewing's, Osteosarcoma, Chronic Lymphocytic Leukemia and Squamous Cell Carcinoma of the Head and Neck.

Originator

Celgene15Sources: https://www.ncbi.nlm.nih.gov/pubmed/26102506

Approval Year

Unknown139594 Targets

Targets

Primary TargetPharmacologyConditionPotency
Serine/threonine-protein kinase mTOR35Target ID: P42345Gene ID: 2475.0Gene Symbol: MTORTarget Organism: Homo sapiens (Human)Sources: https://www.ncbi.nlm.nih.gov/pubmed/26102506 Inhibitor8297 0.021 µM [IC50]
DNA-dependent protein kinase catalytic subunit4Target ID: P78527|||Q9UME3Gene ID: 5591.0Gene Symbol: PRKDCTarget Organism: Homo sapiens (Human)Sources: https://www.ncbi.nlm.nih.gov/pubmed/26102506 Inhibitor8297 0.013 µM [IC50]
Conditions

Conditions

Ewing's osteosarcom1Sources: https://clinicaltrials.gov/show/NCT01353625
ConditionModalityTargetsHighest PhaseProduct
Chronic lymphocytic leukemia59Sources: https://www.ncbi.nlm.nih.gov/pubmed/27235137 Primary Phase I428 Unknown

Approved Use

Unknown
Prostate cancer178Sources: https://clinicaltrials.gov/show/NCT01353625 Primary Phase I428 Unknown

Approved Use

Unknown
Primary Phase I428 Unknown

Approved Use

Unknown
Glioblastoma65Sources: https://clinicaltrials.gov/ct2/show/NCT02977780 Primary Phase II1132 Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
173 ng/mLEXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31853198 25 mg 1 times / day single, oraldose: 25 mgroute of administration: Oralexperiment type: SINGLEco-administered: CC-115 plasma Homo sapienspopulation: UNHEALTHYage: ADULTsex: FEMALE / MALEfood status: FASTED
162 ng/mLEXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31853198 15 mg 2 times / day multiple, oraldose: 15 mgroute of administration: Oralexperiment type: MULTIPLEco-administered: CC-115 plasma Homo sapienspopulation: UNHEALTHYage: ADULTsex: FEMALE / MALEfood status: FASTED
244 ng/mLEXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31853198 40 mg 1 times / day multiple, oraldose: 40 mgroute of administration: Oralexperiment type: MULTIPLEco-administered: CC-115 plasma Homo sapienspopulation: UNHEALTHYage: ADULTsex: FEMALE / MALEfood status: FASTED
51.8 ng/mLEXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31853198 10 mg 2 times / day multiple, oraldose: 10 mgroute of administration: Oralexperiment type: MULTIPLEco-administered: CC-115 plasma Homo sapienspopulation: UNHEALTHYage: ADULTsex: FEMALE / MALEfood status: FASTED
75.2 ng/mLEXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31853198 10 mg 2 times / day multiple, oraldose: 10 mgroute of administration: Oralexperiment type: MULTIPLEco-administered: CC-115 plasma Homo sapienspopulation: UNHEALTHYage: ADULTsex: FEMALE / MALEfood status: FASTED
198 ng/mLEXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31853198 25 mg 1 times / day multiple, oraldose: 25 mgroute of administration: Oralexperiment type: MULTIPLEco-administered: CC-115 plasma Homo sapienspopulation: UNHEALTHYage: ADULTsex: FEMALE / MALEfood status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1716 ng × h/mLEXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31853198 25 mg 1 times / day single, oraldose: 25 mgroute of administration: Oralexperiment type: SINGLEco-administered: CC-115 plasma Homo sapienspopulation: UNHEALTHYage: ADULTsex: FEMALE / MALEfood status: FASTED
2056 ng × h/mLEXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31853198 15 mg 2 times / day multiple, oraldose: 15 mgroute of administration: Oralexperiment type: MULTIPLEco-administered: CC-115 plasma Homo sapienspopulation: UNHEALTHYage: ADULTsex: FEMALE / MALEfood status: FASTED
2650 ng × h/mLEXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31853198 40 mg 1 times / day multiple, oraldose: 40 mgroute of administration: Oralexperiment type: MULTIPLEco-administered: CC-115 plasma Homo sapienspopulation: UNHEALTHYage: ADULTsex: FEMALE / MALEfood status: FASTED
622 ng × h/mLEXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31853198 10 mg 2 times / day multiple, oraldose: 10 mgroute of administration: Oralexperiment type: MULTIPLEco-administered: CC-115 plasma Homo sapienspopulation: UNHEALTHYage: ADULTsex: FEMALE / MALEfood status: FASTED
66 ng × h/mLEXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31853198 10 mg 2 times / day multiple, oraldose: 10 mgroute of administration: Oralexperiment type: MULTIPLEco-administered: CC-115 plasma Homo sapienspopulation: UNHEALTHYage: ADULTsex: FEMALE / MALEfood status: FASTED
1573 ng × h/mLEXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31853198 25 mg 1 times / day multiple, oraldose: 25 mgroute of administration: Oralexperiment type: MULTIPLEco-administered: CC-115 plasma Homo sapienspopulation: UNHEALTHYage: ADULTsex: FEMALE / MALEfood status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.9 hEXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31853198 25 mg 1 times / day single, oraldose: 25 mgroute of administration: Oralexperiment type: SINGLEco-administered: CC-115 plasma Homo sapienspopulation: UNHEALTHYage: ADULTsex: FEMALE / MALEfood status: FASTED
3.98 hEXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31853198 10 mg 2 times / day multiple, oraldose: 10 mgroute of administration: Oralexperiment type: MULTIPLEco-administered: CC-115 plasma Homo sapienspopulation: UNHEALTHYage: ADULTsex: FEMALE / MALEfood status: FASTED
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC 1P000JYN https://www.1pchem.com/search?query=1P000JYN
1PlusChem LLC 1P009D1L https://www.1pchem.com/search?query=1P009D1L
AChemBlock O33758 http://www.achemblock.com/catalogsearch/result/?q=O33758
ApexBio Technology B6114 https://www.apexbt.com/catalogsearch/result/?q=B6114
AstaTech 44159 http://astatechinc.com/CPSResult.php?CRNO=44159
BLD Pharm BD630024 http://www.bldpharm.com/search/Search.html?keyword=BD630024
BLD Pharm BD630098 http://www.bldpharm.com/search/Search.html?keyword=BD630098
Cayman Chemical 19420 http://www.caymanchem.com/app/template/Product.vm/catalog/19420
Chem Scene CS-4561 http://www.chemscene.com/goproductList/searchProductList?productObj=CS-4561
Chem Scene CS-5379 http://www.chemscene.com/goproductList/searchProductList?productObj=CS-5379
ChemShuttle 140477 https://www.chemshuttle.com/catalogsearch/result/?q=140477
KeyOrganics AS-74848 http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-74848
Lab Network LN01341555 https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01341555
MedChem Express HY-16962 https://www.medchemexpress.com/search.html?q=HY-16962A&ft=&fa=&fp=
MedChem Express HY-16962A https://www.medchemexpress.com/search.html?q=HY-16962A&ft=&fa=&fp=
MolPort MolPort-044-183-473 https://www.molport.com/shop/molecule-link/MolPort-044-183-473
MolPort MolPort-044-560-393 https://www.molport.com/shop/molecule-link/MolPort-044-560-393
MolPort MolPort-046-033-571 https://www.molport.com/shop/molecule-link/MolPort-046-033-571
MolPort MolPort-046-417-172 https://www.molport.com/shop/molecule-link/MolPort-046-417-172
MolPort MolPort-046-702-084 https://www.molport.com/shop/molecule-link/MolPort-046-702-084
Molnova M10883 https://www.molnova.com/en/serch-list.html?keywords=M10883
Molnova M11206 https://www.molnova.com/en/serch-list.html?keywords=M11206
MuseChem I005747 https://www.musechem.com/product/I005747.html
ShangHai Biochempartner BCP16702 http://www.biochempartner.com/search_BCP16702
ShangHai Biochempartner BCP20709 http://www.biochempartner.com/search_BCP20709
eMolecules 106929350 https://orderbb.emolecules.com/search/#?query=106929350
eMolecules 208087683 https://orderbb.emolecules.com/search/#?query=208087683
eMolecules 222564514 https://orderbb.emolecules.com/search/#?query=222564514
eMolecules 75542243 https://orderbb.emolecules.com/search/#?query=75542243
eMolecules 89941990 https://orderbb.emolecules.com/search/#?query=89941990
mcule MCULE-3559529294 https://mcule.com/MCULE-3559529294/
mcule MCULE-6536966585 https://mcule.com/MCULE-6536966585/
PubMed

PubMed

TitleDatePubMed
Reversible thiazolidine exchange: a new reaction suitable for dynamic combinatorial chemistry. 2009 Aug 6 19585999
Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115. 2015 Jul 23 26102506
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. 2016 Jul 28 27235137

Sample Use Guides

In Vivo Use Guide Sources: https://clinicaltrials.gov/show/NCT01353625 Dose level starts with 0.5mg daily by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose schedule is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity).Route of Administration: Oral In Vitro Use Guide Sources: https://www.ncbi.nlm.nih.gov/pubmed/27235137 To determine whether combined inhibition of TORK and DNA-PK induces cell death, there were compared CC-115 (range of concentration from 0.001 until 10 uM) to inhibitors that are more specific: CC-214, CC-292, idelalisisb, and NU7441. To correct for variability in viability between thawed primary chronic lymphocytic leukemia (CLL) samples, specific apoptosis was calculated. CC-214 (TORKi), CC-292 (BTKi), idelalisib (PI3Kδi), and NU7441 (DNAPKi) induced modest cell death (IC50 > 10 µM and maximum induction of apoptosis at 10 µM of 30-40 %. Whereas CC-115 induced cell death with an IC50 of 0.51 µM. Cell death was due to on-target inhibition of TORK and DNA-PK, because the combination of the TORK inhibitor CC-214 and the DNA-PK inhibitor NU7441 resulted in cell death comparable to CC-115. CC-115 induced cell death in clinically relevant prognostic CLL subgroups.
Name Type Language
CC-115 Source:
Common Name English
CC-115 [WHO-DD] Source:
Common Name English
1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-B)PYRAZIN-2(1H)-ONE Sources:
Systematic Name English
PYRAZINO(2,3-B)PYRAZIN-2(1H)-ONE, 1-ETHYL-3,4-DIHYDRO-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-5-YL)-3-PYRIDINYL)- Sources:
Systematic Name English
1-ETHYL-7-(2-METHYL-6-(4H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-B)PYRAZIN-2(1H)-ONE Sources:
Systematic Name English
Code System Code Type Description
DRUG BANK Source:
DB12740 Created by admin on Sat Dec 16 08:26:44 GMT 2023 , Edited by admin on Sat Dec 16 08:26:44 GMT 2023 PRIMARY
SMS_ID Source:
300000041470 Created by admin on Sat Dec 16 08:26:44 GMT 2023 , Edited by admin on Sat Dec 16 08:26:44 GMT 2023 PRIMARY
NCI_THESAURUS Source:
C97040 Created by admin on Sat Dec 16 08:26:44 GMT 2023 , Edited by admin on Sat Dec 16 08:26:44 GMT 2023 PRIMARY
ChEMBL Source:
CHEMBL3545426 Created by admin on Sat Dec 16 08:26:44 GMT 2023 , Edited by admin on Sat Dec 16 08:26:44 GMT 2023 PRIMARY
CAS Sources:
1228013-15-7 Created by admin on Sat Dec 16 08:26:44 GMT 2023 , Edited by admin on Sat Dec 16 08:26:44 GMT 2023 PRIMARY
FDA UNII
FII75TFH5L Created by admin on Sat Dec 16 08:26:44 GMT 2023 , Edited by admin on Sat Dec 16 08:26:44 GMT 2023 PRIMARY
PUBCHEM Source:
58298318 Created by admin on Sat Dec 16 08:26:44 GMT 2023 , Edited by admin on Sat Dec 16 08:26:44 GMT 2023 PRIMARY
ACTIVE MOIETY FII75TFH5L Structure of CC-115 CC-115 NIH NCATS PRIVACY ACT ACCESSIBILITY DISCLAIMER HHS VULNERABILITY DISCLOSURE For language access assistance, contact the NCATS Public Information Officer National Center for Advancing Translational Sciences (NCATS), 6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966 version 1.1

Từ khóa » Cc-115